Cantor Maintains Upgrades Endo To Hold But Sees 20% Downside For The Stock
In a research report published Friday, Cantor analyst Irina Rivkind maintained a Hold rating on Endo Health Solutions (NASDAQ:ENDP) with a price target of $56, which represents a potential downside of 20% from where the stock is currently trading.
Rivkind explained, “Though we take a conservative view of Auxilium’s portfolio, we believe that Endo can attain +6.7% EPS accretion in 2015, with longer-term increases in EBITDA to facilitate additional M&A. We are not expecting meaningful deal flow over the next six months while Endo pays down a large portion of its mesh litigation settlement and works to integrate Auxilium. We believe that the worst is over and there is more visibility into longer-term growth. Our prior SELL rating was predicated on valuation, not catalysts. For these reasons, we upgrade ENDP to HOLD.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a total average return of 14.7% and a 62.7% success rate. Rivkind Koffler has a -2.5% average return when recommending ENDP, and is ranked #171 out of 3364 analysts.